University of Hawai‘i at Manoa Homepage


Jeffrey Huang, PharmD

Jeffrey Huang, PharmD
  • Clinical Member
    Translational & Clinical Research
    University of Hawaii Cancer Center
  • Assistant Specialist / Investigator-Initiated Trials/Phase 1 Division Lead
    Clinical & Translational Research Program
    University of Hawai'i Cancer Center


  • Doctor of Pharmacy (PharmD)
    University of Michigan - College of Pharmacy
    Ann Arbor, Michigan
  • Drug Development and Clinical Research Fellowship
    University of North Carolina - Eshelman School of Pharmacy / GlaxoSmithKline
    Chapel Hill, North Carolina

Research Focus

Centrally located in the Pacific Ocean, Hawaii has the opportunity to serve as an oncology research hub between the Pacific Asian countries and the United States. The diverse racial and ethnic mixture in Hawaii's population makes the state unique in the types and incidences of cancer encountered.

The University of Hawaii Cancer Center has organized focus groups targeting the cancers that has the highest impact on the diverse Hawaiian population. My current and future research interests are to collaborate with principal investigators, research experts, and scientists to explore these cancer indications, with the goal of reducing disease burden through investigator-initiated and early phase clinical trials.

Current projects and research interests include drafting, revising, and submitting for approval the following clinical studies:

  • Denosumab plus Enzalutamide, Abiraterone, and Prednisone compared to Denosumab plus Enzalutamide alone for men with Castrate Resistant Prostate Cancer (CRPC) with bone metastases: clinical testing and feasibility of a serum-based metabolomics profile
    Primary objective: To compare the overall survival of patients with progressive metastatic CRPC treated with either a) enzalutamide only or b) enzalutamide with abiraterone and prednisone
  • Phase II Clinical Study of Noni Extract in Men with Very Low Risk or Low Risk Prostate Cancer
    Primary objective: To evaluate the Genomic Prostate Score (GPS, and associated gene expression changes) in prostatic tumors in men treated with Noni extract (6,200 mg/day) for one year following the diagnosis of very low risk or low risk prostate cancer.
  • Phase Ib study assessing a sequencing regimens of MPDL3280A and sipuleucel-T in patients who have asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
    Primary Objective: To characterize the molecular changes (i.e., reduction in quantity of cell free DNA associated with tumor) and induction of favorable genomic profile associated with RNA from circulating tumor cells and peripheral blood mononuclear cells (PBMC) between the two study arms.
  • Quantitating the Expression of PD-L1 in Non-Muscle Invasive Bladder Cancer and Resected Gastric and Gastroesophageal Adenocarcinoma
    Primary Objective: To investigate and correlate the expression of PD-L1 to disease outcomes in bladder and gastric cancer
  • Smoking cessation in bladder cancer feasibility study
    Primary Objective: To assess bladder tumor recurrence at 24 months in early intervention smoking cessation groups.

My future research interests are to continue increasing the opportunities for the Hawaiian population to explore innovative investigator-initiated and early phase clinical trials. As the number of trials begin to grow, I am excited for the opportunity to serve as a principal investigator on future studies, utilizing my clinical experience as a Pharm.D. from the University of Michigan College of Pharmacy, clinical research experience from my fellowship at the University of North Carolina Eschelman School of Pharmacy / GlaxoSmithKline, as well as my oncology drug development and clinical pharmacology experience as a reviewer for the Food and Drug Administration (FDA).